COLFAX

THIRD QUARTER 2019 | EARNINGS CONFERENCE CALL

Forward Looking Statements & Non-GAAP Disclaimer

The following information may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission including its 2018 Annual Report on Form 10-K under the caption "Risk Factors." In addition, these statements are based on a number of assumptions that are subject to change. These materials speak only as of the date hereof. Colfax disclaims any duty to update the information herein, except as required by law.

Colfax has provided in this presentation financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, adjusted EBITA, (earnings before interest, taxes and amortization), adjusted EBITDA, and Existing Business or organic sales growth (decline). Colfax also provides adjusted EBITA and EBITDA on a segment basis.

- Adjusted net income from continuing operations represents net income (loss) from continuing operations attributable to Colfax excluding restructuring and other related charges, pension settlement loss, debt extinguishment charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs. The effective tax rates used to calculate adjusted net income and adjusted net income per share were 26.2% for the three months ended September 27, 2019 and 32.5% for the three months ended September 28, 2018. Adjusted net income per share represents adjusted net income as defined above divided by the weighted-average diluted shares outstanding.
- Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, pension settlement loss, acquisition-related amortization and other non-cash charges, and strategic transaction costs, as well as provision (benefit) for income taxes, and interest expense, net. Adjusted EBITDA incrementally excludes depreciation and other amortization. We also present Adjusted EBITA margin and Adjusted EBITDA margin, which are subject to the same adjustments as Adjusted EBITA and Adjusted EBITDA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) and adjusted EBITDA (and adjusted EBITDA margin) on a segment basis, where it excludes the impact of strategic transaction costs, and acquisition-related amortization and other non-cash charges. Adjusted EBITDA (and adjusted EBITDA margin) on a segment basis is subject to the same adjustments as Adjusted EBITA and also excludes depreciation and other amortization.
- Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.

These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business performance and trends.

Q3 2019 Highlights

- Recently completed portfolio transformation with close of Air & Gas Handling transaction; proceeds used to pay down debt
- Achieved financial results at the upper end of expectations; reaffirming full year guidance
- Accelerated organic growth rate in MedTech
- Delivered strong FabTech margins in softer market conditions

Medical Technology Momentum Continues

millions

- Organic growth progress
  - Prevention & Rehabilitation returns to positive growth in Q3 with growth of 3.2%
  - Reconstructive strength continues at 8.1% fueled by double-digit surgical performance
- EBITA margin up 200 bps sequentially, 18.5% vs. 16.5% in Q2
- Cost reductions & productivity beginning to read through – expect another step up in Q4 supported by seasonally stronger volume

Q3 Sales

vs. Q3 2018

Existing Businesses	4.5 %
Acquisitions	0.4 %
FX Translation	(1.0) %
Total Change	3.9 %

Adjusted EBITA / Margin



COLFAX

Note: Refer to Appendix for non-GAAP reconciliation and footnotes.

Building a Strong Platform for Sustained Growth

MedTech Quarterly YoY Organic Growth, FY19



- Results to date include year-on-year tailwind from solid execution of ongoing operational improvements
- Reconstructive share gain reflects new product releases and surgeon conversion
- Prevention & Rehabilitation return to positive growth in 2H demonstrates market leadership
- Expect fourth quarter growth of 5.5%+ including the benefit of one extra sales day

Fabrication Technology Growth and Profitability

- 15% aEBITA margin up 290 bps from prior year on lower volume
  - Continuing read-through of cost and productivity efforts
  - Proactive price / cost management
- Markets softer in North America and Europe through the quarter
  - Continued organic growth in emerging markets
- Line of sight to achieve significant YOY margin expansion in Q4

millions

Q3 Sales



vs. Q3 2018

Volume	(3.3) %
Price	2.8 %
Acquisitions	6.3 %
FX Translation	(2.8) %
Total Change	2.9 %

May include rounding differences

Q3 Adjusted EBITA / Margin



Note: Refer to Appendix for non-GAAP reconciliation and footnotes.

COLFAX

Strong Margin Improvement Journey

Fabrication Technology adj. EBITA Margin Growth



- ~340 bps of margin improvement:
  - Capturing operating leverage
  - CBS productivity
  - Disciplined site consolidation (47 sites to 34)
  - Proactive price / cost management
  - Acquiring differentiated businesses and product lines
  - New product development
- Demonstrated ability to expand margins throughout a range of end market conditions
- Path for continued margin expansion

Note: Refer to Appendix for non-GAAP reconciliation and footnotes.

The Power of the New Colfax Portfolio

Market-leading positions in attractive markets





- Long-term demographic & secular growth drivers
- Significant bolt-on and adjacent acquisition runway

Less cyclical sales and cash flow

> 90%
Sales from recurring, run-rate products

> 90%
Expected FCF conversion in 2020[1]

- Non-cyclical Medical Technology segment
- Higher, stable cash generation throughout economic cycles

Structurally higher margins with meaningful upside

> 40%
Gross margins with industry-defining products and brands

> 55%
Gross margins in MedTech

- Use CBS to improve margins
- Innovation & acquisitions to improve mix

(1) Calculated as (Cash flow from operating activities – Capital expenditures) / Adjusted net income.

COLFAX

Q3 2019 Financial Highlights

	Continuing Operations[1] Q3 2018	Q3 2019
Net sales	$524	$847
Gross profit	$171	$368
Margin	32.7%	43.5%
Adj. EBITA	$50	$126
Margin	9.6%	14.9%
Adj. EBITDA	$60	$153
Margin	11.5%	18.0%
Adj. EPS	$0.22	$0.50

- Organic growth of 1.3%, DJO acquisition contributed to sales growth
- Margin improvement from higher MedTech margin structure and strong FabTech operating performance
- Operational performance ahead of expectation, partially offset by higher taxes
- $1.6 billion debt repaid beginning of Q4 from proceeds of Air & Gas Handling divestiture
- Pension de-risking complete; liability reduced 80% in recent years

Reaffirming guidance of $1.90 – $2.00

Note: In millions, except per share amounts. Refer to Appendix for non-GAAP reconciliation and footnotes.
(1) Continuing operations excludes A&GH business and interest expense associated with expected debt paydown from A&GH closing

COLFAX

Summary

- Completed pivot to a less cyclical, higher margin, better growth outlook portfolio
- Demonstrating solid operational and commercial execution at ESAB to expands margins
- Making strong growth and operational progress at DJO
- Reaffirming full year adj. EPS guidance range of $1.90 - $2.00

COLFAX

COLFAX

APPENDIX

Change in Sales

	Three Months Ended	
	$	%
For the three months ended September 28, 2018	$ 524.0	
Components of change:		
Existing businesses[1]	(3.2)	-0.6%
Acquisitions[2]	340.4	65.0%
Foreign currency translation[3]	(14.7)	-2.8%
	322.5	61.5%
For the three months ended September 27, 2019	**$ 846.5**	

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.
(2) Represents the incremental sales for acquisitions completed in our Fabrication Technology segment and acquisition of our Medical Technology segment.
(3) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Note: Dollars in millions

COLFAX

Non-GAAP Reconciliation

	Three Months Ended September 27, 2019											
	Fabrication Technology			Medical Technology			Corporate and Other		Total Continuing Operations Colfax Corporation			
Net sales	$	539.2		$	307.3		$	-	$	846.5	
Segment operating income		73.0	13.5%		22.5	7.3%		(14.3)		81.2	9.6%
Strategic transaction costs		-			-			0.9		0.9	0.1%
Adjusted operating profit	**$**	**73.0**	**13.5%**	**$**	**22.5**	**7.3%**	**$**	**(13.4)**	**$**	**82.0**	**9.7%**
Acquisition-related amortization and other non-cash charges[1]		9.2	1.7%		34.5	11.2%		0.0		43.7	5.2%
Adjusted EBITA	**$**	**82.2**	**15.2%**	**$**	**56.9**	**18.5%**	**$**	**(13.4)**	**$**	**125.8**	**14.9%**
Depreciation and other amortization		10.7	2.0%		15.7	5.1%		0.3		26.8	3.2%
Adjusted EBITDA	**$**	**93.0**	**17.2%**	**$**	**72.6**	**23.6%**	**$**	**(13.1)**	**$**	**152.5**	**18.0%**

	Three Months Ended September 28, 2018										
	Fabrication Technology			Medical Technology		Corporate and Other		Total Continuing Operations Colfax Corporation		
Net sales	$	524.0		$	-	$	-	$	524.0	
Segment operating income		55.6	10.6%		-		(13.9)		41.7	8.0%
Strategic transaction costs		-			-		-		-	
Adjusted operating profit	**$**	**55.6**	**10.6%**	**$**	**-**	**$**	**(13.9)**	**$**	**41.7**	**8.0%**
Acquisition-related amortization and other non-cash charges[1]		8.7	1.7%		-		0.0		8.7	1.7%
Adjusted EBITA	**$**	**64.3**	**12.3%**	**$**	**-**	**$**	**(13.9)**	**$**	**50.4**	**9.6%**
Depreciation and other amortization		9.6	1.8%		-		0.4		9.9	1.9%
Adjusted EBITDA	**$**	**73.9**	**14.1%**	**$**	**-**	**$**	**(13.5)**	**$**	**60.3**	**11.5%**

(1) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.

COLFAX

Non-GAAP Reconciliation

	Fabrication Technology							
	Years Ended December 31,							
	2015		2016		2017		2018	
Net sales	$ 1,985.2		$ 1,800.5		$ 1,937.3		$ 2,193.1	
Segment operating income	199.8	10.1%	195.4	10.9%	224.4	11.6%	249.9	11.4%
Strategic transaction costs	-		0.5		0.0		0.0	
Adjusted operating profit	**$ 199.8**	**10.1%**	**$ 195.9**	**10.9%**	**$ 224.4**	**11.6%**	**$ 250.0**	**11.4%**
Acquisition-related amortization and other non-cash charges[1]	29.4	1.5%	30.4	1.7%	31.9	1.6%	39.8	1.8%
Adjusted EBITA	**$ 229.2**	**11.5%**	**$ 226.3**	**12.6%**	**$ 256.3**	**13.2%**	**$ 289.8**	**13.2%**

(1) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.

COLFAX

Non-GAAP Reconciliation

	Three Months Ended	
	September 27, 2019	September 28, 2018
Net income from continuing operations	$ 3.8	$ 16.7
Provision (benefit) for income taxes	(1.4)	6.8
Interest expense, net	31.8	11.6
Pension settlement loss	33.6	-
Restructuring and other related charges(1)	13.3	6.7
Strategic transaction costs	0.9	-
Adjusted operating profit	**$ 82.0**	**$ 41.7**
Adjusted operating profit margin	**9.7%**	**8.0%**
Acquisition-related amortization and other non-cash charges(2)	43.7	8.7
Adjusted EBITA	**$ 125.8**	**$ 50.4**
Adjusted EBITA margin	**14.9%**	**9.6%**
Depreciation and other amortization	26.8	9.9
Adjusted EBITDA	**$ 152.5**	**$ 60.3**
Adjusted EBITDA margin	**18.0%**	**11.5%**

(1) Includes $3.5 million of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three months ended September 27, 2019.
(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.

Non-GAAP Reconciliation

	Three Months Ended	
	September 27, 2019	September 28, 2018
Adjusted Net Income and Adjusted Net Income Per Share		
Net income from continuing operations attributable to Colfax Corporation[(1)]	$ 2.9	$ 16.2
Restructuring and other related charges - pretax[(2)]	13.3	6.7
Pension settlement loss - pretax	33.6	-
Acquisition-related amortization and other non-cash charges - pretax[(3)]	43.7	8.7
Strategic transaction costs - pretax	0.9	-
Tax adjustment[(4)]	(26.0)	(5.8)
Adjusted net income from continuing operations	$ 68.5	$ 25.7
Adjusted net income per share continuing operations	$ 0.50	$ 0.22
Net income per share - diluted from continuing operations (GAAP)	$ 0.02	$ 0.14

(1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes of $0.9 million for the three months ended September 27, 2019 and $0.4 million for the three months ended September 28, 2018.
(2) Includes $3.5 million of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three months ended September 27, 2019.
(3) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
(4) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 26.2% for the three months ended September 27, 2019 and 32.5% for the three months ended September 28, 2018.

Note: Dollars in millions, except per share amounts. Some periods may not foot due to rounding.